March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Five-Year Follow Up Of Ranibizumab For Retinal Vein Occlusion: Intermittent Treatment To Control Edema Does Not Prevent Progressive Worsening Of Retinal Nonperfusion
Raafay Sophie; Gulnar Hafiz; Diana V. Do; Quan D. Nguyen; Sharon Solomon; Ingrid Zimmer-Galler; Howard Ying; Adrienne W. Scott; David Baranano; Peter A. Campochiaro
Author Affiliations & Notes
  • Raafay Sophie
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Gulnar Hafiz
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Diana V. Do
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Quan D. Nguyen
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Sharon Solomon
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Ingrid Zimmer-Galler
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Howard Ying
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Adrienne W. Scott
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • David Baranano
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Peter A. Campochiaro
    Ophthalmology, Wilmer Eye Institute Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Raafay Sophie, None; Gulnar Hafiz, None; Diana V. Do, Genentech (F), Regeneron (F); Quan D. Nguyen, Bausch and Lomb (C), Genentech (F), Regeneron (F), Santen (F, C); Sharon Solomon, None; Ingrid Zimmer-Galler, None; Howard Ying, None; Adrienne W. Scott, None; David Baranano, None; Peter A. Campochiaro, Alcon Laboratories, Inc. (F), Alimera (F), Allergan (C), Genentech (F, C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Five-Year Follow Up Of Ranibizumab For Retinal Vein Occlusion: Intermittent Treatment To Control Edema Does Not Prevent Progressive Worsening Of Retinal Nonperfusion
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Raafay Sophie, Gulnar Hafiz, Diana V. Do, Quan D. Nguyen, Sharon Solomon, Ingrid Zimmer-Galler, Howard Ying, Adrienne W. Scott, David Baranano, Peter A. Campochiaro; Five-Year Follow Up Of Ranibizumab For Retinal Vein Occlusion: Intermittent Treatment To Control Edema Does Not Prevent Progressive Worsening Of Retinal Nonperfusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):918.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To assess the long term effect of intermittent treatment with ranibizumab (RBZ) to control macular edema on visual outcome and retinal nonperfusion (RNP) in patients with retinal vein occlusion (RVO).

Methods: : 20 patients with BRVO and 20 patients with CRVO were treated with 3 monthly RBZ injections and then seen every two months and treated with RBZ as needed to control edema. Fluorescein angiograms were done at several time points throughout the 5 years of follow up and RNP was graded.

Results: : Of 11 patients with BRVO who completed 5 years of follow up, the amount RNP at baseline was none in one, mild in one, moderate in 3, severe in 3, and ungradable in 3. Two patients showed improvement in RNP at month 3 (M3) and none showed worsening. Between M3 and 5 years, 6 patients showed worsening of RNP causing severe loss of BCVA in 3, and 5 patients showed no change. The peak mean improvement in BCVA was 22.1 letters and the mean improvement at 5 years was 13 letters due primarily to RNP-related loss of BCVA. Of 10 patients with CRVO who completed 5 years of follow up, the amount of RNP at baseline was none in one, mild in 4, moderate in 2, and ungradable in 3. All 6 patients with gradable RNP showed improvement at M3. Between M3 and 5 years, 4 patients showed worsening of RNP causing severe loss of BCVA in 2, and 6 showed no definite change RNP. The peak mean improvement in BCVA was 19.7 letters and the mean improvement at 5 years was 8.4 letters due primarily to RNP-related loss of BCVA.

Conclusions: : In patients with RVO, RNP improved or remained unchanged after 3 monthly injections of RBZ, but during 57 months of infrequent injections, several patients showed worsening of RNP and loss of vision. Over the course of 5 years, infrequent treatment with RBZ to control edema may not be sufficient to prevent worsening of RNP and loss of BCVA in some patients.

Clinical Trial: : http://www.clinicaltrials.gov NCT00407355

Keywords: ischemia • retina • visual acuity 
© 2012, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept